BioAtla, Inc.

Quick facts

Phase 2 pipeline

• CAB-AXL-ADC · Oncology
  CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding.

Phase 1 pipeline

• BA3071
• BA3182
• CAB-ROR2-ADC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioAtla, Inc. portfolio CI brief
• BioAtla, Inc. pipeline updates RSS